(Q37226168)

English

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

scientific article published on 23 July 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention (English)

1 reference

Europe PubMed Central

19 August 2017

0 references

1 reference

based on heuristic

inferred from title

cervix uterine cancer

1 reference

based on heuristic

inferred from title

author name string

David Jenkins

1

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

23 July 2008

1 reference

Europe PubMed Central

19 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

19 August 2017

110

1 reference

Europe PubMed Central

19 August 2017

S18-25

1 reference

Europe PubMed Central

19 August 2017

3 Suppl 1

1 reference

Europe PubMed Central

19 August 2017

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Re: A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Chapter 2: The burden of HPV-related cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Classification of papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Cervical Coinfection with Human Papillomavirus (HPV) Types and Possible Implications for the Prevention of Cervical Cancer by HPV Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Prevalence of HPV infection among females in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

The Authors Respond to "HPV Persistence and Cervical Cancer Screening"

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Viral load as a predictor of the risk of cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Clinical utility of HPV genotyping

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Carcinogenicity of human papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.027

7 January 2021

Identifiers

10.1016/J.YGYNO.2008.06.027

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37226168&oldid=2147740717"